Home  About us  Contact
 

Pyridine Series (pyridine + series)

Distribution by Scientific Domains
Chemistry100%

Selected Abstracts

Side-Chain Retention During Lithiation of 4-Picoline and 3,4-Lutidine: Easy Access to Molecular Diversity in Pyridine Series

EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, Issue 19 2003
Thomas Kaminski
Abstract The first direct ring-selective lithiation of 4-picoline and 3,4-lutidine has been achieved through the use of BuLi/LiDMAE aggregates to prevent the usual side-chain metallation. Several functionalities have been introduced at the C-2, C-6 and C-5 positions by ring-selective sequential lithiation, opening a simple and fast route to polysubstituted pyridine building blocks. (© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003) [source]

ChemInform Abstract: Microwave-Assisted Double Suzuki,Miyaura Cross-Coupling in the 6,8-Dibromoimidazo[1,2-a]pyridine Series.

CHEMINFORM, Issue 22 2008
Remi Szabo
Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a "Full Text" option. The original article is trackable via the "References" option. [source]

Evaluation of the 2-Substituent Effect on the Reactivity of the 8-Haloimidazo[1,2-a]pyridine Series (III) Towards Suzuki-Type Cross-Coupling Reaction.

CHEMINFORM, Issue 21 2005
Jean-Yves Kazock
No abstract is available for this article. [source]

Synthesis and Biological Evaluation of Some Polymethoxylated Fused Pyridine Ring Systems as Antitumor Agents

ARCHIV DER PHARMAZIE, Issue 10 2009
Sherif A. F. Rostom
Abstract A series of 3,5- bis(arylidene)-4-piperidones like chalcone analogues carrying variety of methoxylated aryl groups, pyrazolo[4,3- c]pyridines, pyrido[4,3- d]pyrimidines, and pyrido[3,2- c]pyridines, carrying an arylidene moiety, and some pyrano[3,2- c]pyridines, like flavone and coumarin isosteres, were synthesized and screened for their in-vitro antitumor activity at the National Cancer Institute (NCI, USA). The tested compounds 7, 9, 10, 12, 13, 15, 17, and 19 exhibited a broad spectrum of antitumor activity. Compounds belonging to the pyrazolo[4,3- c]pyridine series proved to be more active than those of the pyrido[3,2- c]pyridine and pyrano[3,2- c]pyridine analogues, in which the monomethoxylated derivatives showed better antitumor activity when compared with their corresponding dimethoxylated congeners. Compound 7 is considered to be the most active member identified in this study with a broad spectrum of activity against 22 different tumor cell lines belonging to the nine subpanels employed, and a particular effectiveness against the breast cancer T-47D cell line (GI 54.7%). The pyrano[3,2- c]pyridine heterocyclic system 19 proved to be the most active antitumor agent among the six-membered fused pyridines, with variable activity against 18 different tumor cell lines, and special activity against the non-small cell lung cancer Hop-92 and ovarian cancer OVCAR-4 cell lines (GI values 63.9 and 48.5%, respectively). [source]